Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytosorbents Corporation (CTSO) stocks in Canada

Learn how to easily invest in Cytosorbents Corporation stocks.

Cytosorbents Corporation is a medical devices business based in the US. Cytosorbents Corporation stocks (CTSO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.68 – an increase of 4.39% over the previous week. Cytosorbents Corporation employs 195 staff and has a trailing 12-month revenue of around $44.3 million.

How to buy shares in Cytosorbents Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTSO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cytosorbents Corporation stock price (NASDAQ:CTSO)

Use our graph to track the performance of CTSO stocks over time.

Cytosorbents Corporation shares at a glance

Information last updated 2022-01-23.
Latest market close$3.57
52-week range$3.18 - $11.68
50-day moving average $4.78
200-day moving average $7.17
Wall St. target price$12.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.37

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cytosorbents Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cytosorbents Corporation price performance over time

Historical closes compared with the close of $3.57 from 2022-01-25

1 week (2022-01-19) 4.39%
1 month (2021-12-23) -19.78%
3 months (2021-10-26) -38.77%
6 months (2021-07-26) -51.76%
1 year (2021-01-26) -61.61%
2 years (2020-01-24) -22.56%
3 years (2019-01-25) 7.22
5 years (2017-01-26) 5.65

Cytosorbents Corporation financials

Revenue TTM $44.3 million
Gross profit TTM $30 million
Return on assets TTM -9.92%
Return on equity TTM -21.12%
Profit margin -35.93%
Book value $1.62
Market capitalisation $148.7 million

TTM: trailing 12 months

Cytosorbents Corporation share dividends

We're not expecting Cytosorbents Corporation to pay a dividend over the next 12 months.

Have Cytosorbents Corporation's shares ever split?

Cytosorbents Corporation's shares were split on a 1:25 basis on 4 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Corporation shares which in turn could have impacted Cytosorbents Corporation's share price.

Cytosorbents Corporation share price volatility

Over the last 12 months, Cytosorbents Corporation's shares have ranged in value from as little as $3.18 up to $11.684. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Corporation's is 0.2544. This would suggest that Cytosorbents Corporation's shares are less volatile than average (for this exchange).

Cytosorbents Corporation overview

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site